Wellington Management Group LLP Increases Position in Fulcrum Therapeutics, Inc. $FULC

Wellington Management Group LLP lifted its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 140.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 285,084 shares of the company’s stock after purchasing an additional 166,484 shares during the period. Wellington Management Group LLP’s holdings in Fulcrum Therapeutics were worth $1,043,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Fulcrum Therapeutics in the second quarter valued at about $32,297,000. Nantahala Capital Management LLC purchased a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth approximately $20,038,646. Braidwell LP grew its holdings in shares of Fulcrum Therapeutics by 1,294.7% in the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock worth $34,622,000 after acquiring an additional 2,841,734 shares during the period. Siren L.L.C. acquired a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $22,054,000. Finally, First Turn Management LLC purchased a new position in Fulcrum Therapeutics in the 4th quarter valued at approximately $21,406,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Wall Street Analyst Weigh In

FULC has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Friday, July 17th. HC Wainwright lowered Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 target price on the stock. in a report on Tuesday, June 2nd. Truist Financial cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research report on Tuesday, June 2nd. JPMorgan Chase & Co. downgraded Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Wednesday, June 3rd. Finally, Piper Sandler lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $8.20.

Insider Buying and Selling at Fulcrum Therapeutics

In other news, Director Alan Ezekowitz sold 18,000 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the transaction, the director directly owned 10,927 shares of the company’s stock, valued at $39,883.55. The trade was a 62.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.30% of the stock is currently owned by company insiders.

Fulcrum Therapeutics Price Performance

Shares of FULC opened at $3.80 on Friday. Fulcrum Therapeutics, Inc. has a 1-year low of $2.83 and a 1-year high of $15.74. The stock has a market cap of $289.93 million, a price-to-earnings ratio of -3.14 and a beta of 2.59. The firm has a 50 day simple moving average of $3.75 and a 200-day simple moving average of $5.52.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). On average, equities analysts expect that Fulcrum Therapeutics, Inc. will post -0.69 earnings per share for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.